Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Granisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 12/20 | 0.96 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | HTR3B | O95264 | 1/20 | 0.96 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.96 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.96 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.96 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.96 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Granisetron SCHEMBL5060939 | 0.99 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL5067161 | 0.98 | HTR3A (0.96) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL34178 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13660190 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL29372622 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL16642163 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4109977 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL445223 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4890 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13287290 | 0.98 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-07-10 | — | — | US | disclosed |
| EP-4364742-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | Eisai R&D Management Co., Ltd. (JP) | 2024-05-08 | — | — | EP | disclosed |
| CN-117794544-A | Pharmaceutical composition for treating solid tumor | 卫材R&D管理有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023038030-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-03-16 | — | — | WO | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| CN-107921033-B | Bioadhesive compositions of granisetron for intranasal administration | 美治医药科技有限公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-3078367-B1 | BIOADHESIVE COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF GRANISETRON | MAXINASE LIFE SCIENCES LTD (HK) | 2020-07-22 | — | — | EP | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019180176-A1 | COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA AND/OR PSYCHOSIS | SPHERIUM BIOMED, S.L. (ES) | 2019-09-26 | — | — | WO | disclosed |
| US-10335398-B2 | Bioadhesive compositions for intranasal administration of granisetron | MAXINASE LIFE SCIENCES LIMITED (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | HTR3A 574/4885HTR3E 1038/4885SLC22A2 4113/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR3A 3141/4885HTR3E 2780/4885SLC22A2 4769/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | HTR3A 1245/4885HTR3E 1685/4885SLC22A2 4616/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | HTR3A 384/4885HTR3E 442/4885SLC22A2 4352/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR3A 353/4885HTR3E 504/4885SLC22A2 4714/4885 |
| US-10335398-B2 | Bioadhesive compositions for intranasal administration of granisetron | VIP, SLC18A1, GALR1 | HTR3A 41/4885HTR3E 170/4885SLC22A2 774/4885 |
| US-20250222003-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING SOLID TUMORS | HTR3C, HTR3D, HTR3A | HTR3A 3/4885HTR3E 7/4885SLC22A2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.